AstraZeneca’s Symbicort Turbuhaler (budesonide/formoterol 160/4.5mcg) has been approved in China as an anti-inflammatory reliever to be taken as-needed in response ...
(RTTNews) - AstraZeneca Plc (AZN.L, AZN) announced the approval of the company's Symbicort Turbuhaler in China as an anti-inflammatory reliever to be taken as-needed in response to symptoms to achieve ...
AstraZeneca has unveiled data from two Phase III trials showing the benefit of using Symbicort Turbuhaler as an anti-inflammatory reliever ‘as needed’ versus two different treatment regimens in ...
MISSISSAUGA, ON, Sept. 30, 2019 /CNW/ - AstraZeneca Canada announced today that Health Canada has approved the expanded use of Symbicort ® Turbuhaler ® (budesonide ...
Symbicort Turbuhaler approved in China asan anti-inflammatory reliever in mild asthma Symbicort Turbuhaler becomes the first dual-combinationtherapy approved in China for mild, moderate and severe ...
The results showed a a 51% reduction in the rate of annual asthma exacerbations compared to albuterol. AstraZeneca’s Novel START trial for its Symbicort Turbuhaler ...
TOKYO, June 22 (Reuters) - Astellas Pharma Inc said on Friday it has received approval for additional use of its Symbicort Turbuhaler drug treatment for adult bronchial asthma in Japan beyond its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback